

**AMENDMENTS TO THE CLAIMS**

1. **(Currently Amended)** A newborn ~~NOD/SCID/IL2rg-null~~ SCID/IL2rg-null mammal (excluding human), into which human-derived hematopoietic stem or precursor cells have been transplanted, and which is able to generate immunocompetent cells derived from said human-derived hematopoietic stem or precursor cells and/or physiologically active substances derived from said immunocompetent cells, wherein the immunocompetent cells comprise B cells, T cells and dendritic cells.

2. **(Currently Amended)** An immunodeficient mammal obtained as a result of the breeding of a newborn ~~NOD/SCID/IL2rg-null~~ SCID/IL2rg-null mammal (excluding human), into which human-derived hematopoietic stem or precursor cells have been transplanted, and which is able to generate immunocompetent cells derived from said human-derived hematopoietic stem or precursor cells and/or physiologically active substances derived from said immunocompetent cells, or a progeny thereof, wherein the immunocompetent cells comprise B cells, T cells and dendritic cells.

3. (Cancelled)

4. (Previously Presented) The newborn mammal according to claim 1, wherein the hematopoietic stem or precursor cells are derived from bone marrow, cord blood, or peripheral blood.

5. **(Currently Amended)** The newborn mammal according to claim 1, wherein the immunocompetent cells ~~are at least one selected from the group consisting of B cells, T cells, dendritic cells,~~ further comprise NK cells, NK cells and NKT cells.

6. **(Currently Amended)** The newborn mammal according to claim 1, wherein the physiologically active substance is a cytokine and/or an immunoglobulin, wherein the immunoglobulin comprises IgG, IgM, IgA and IgD.

7. **(Currently Amended)** The newborn mammal according to claim 6, wherein the immunoglobulin is ~~any one selected from the group consisting of IgG, IgM, IgA, IgD, and~~ further comprises IgE.

8. **(Currently Amended)** The newborn mammal according to ~~claim 1~~ any one of claims 1, 4, 5, 6 or 7, wherein the ~~NOD/SCID/IL2rg-null~~ SCID/IL2rg-null mammal is an NOD/SCID/IL2rg-null mouse.

9. **(Withdrawn)** A method for producing a mammal capable of generating immunocompetent cells derived from a human and/or physiologically active substances derived from said immunocompetent cells, or a progeny thereof, which is characterized in that it comprises transplantation of human-derived hematopoietic precursor cells or mature hematopoietic cells into an immature immunodeficient mammal (excluding said human).

10. (Withdrawn) The method according to claim 9, wherein the immature immunodeficient mammal is a newborn immunodeficient mammal or a fetal immunodeficient mammal.

11. (Withdrawn) The method according to claim 9, wherein the hematopoietic precursor cells are derived from bone marrow, cord blood, or peripheral blood.

12. (Withdrawn) The method according to claim 9, wherein the immunocompetent cells are at least one selected from the group consisting of B cells, T cells, dendritic cells, NK cells, and NKT cells.

13. (Withdrawn) The method according to claim 9, wherein the physiologically active substance is a cytokine and/or an immunoglobulin.

14. (Withdrawn) The method according to claim 13, wherein the immunoglobulin is any one selected from the group consisting of IgG, IgM, IgA, IgD, and IgE.

15. (Withdrawn) The method according to claim 9, wherein the immunodeficient mammal is an immunodeficient mouse.

16. (Withdrawn) A method for producing a human-derived antibody, which is characterized in that it comprises recovering immunocompetent cells from the mammal

according to claim 1, or the mammal or a progeny thereof, culturing said immunocompetent cells in the presence of an antigen or a stimulator, and collecting said human-derived antibody from the obtained culture product.

17. (Withdrawn) The method according to claim 16, wherein the immunocompetent cells are at least one selected from the group consisting of B cells, T cells, dendritic cells, NK cells, and NKT cells.

18. (Withdrawn) A method for producing a human-derived antibody, which is characterized in that it comprises immunizing the mammal according to claim 1, or the mammal or a progeny thereof, with an antigen or a stimulator, and collecting said human-derived antibody from the immunized mammal.

19. (Withdrawn) The method according to claim 18, wherein the antibody is collected from blood plasma or serum.

20. (Withdrawn) A disease-model mammal, which is produced by administering to the mammal according to claim 1, or the mammal or a progeny thereof, any one selected from the group consisting of bacteria, viruses, tumor cells, and tumor antigen peptides, or a progeny thereof.

21. (Withdrawn) The mammal according to claim 20 or a progeny thereof, wherein the disease is an infectious disease.

22. (Withdrawn) A method for screening for an immune-related pharmaceutical, which is characterized in that it comprises administering a test substance to the mammal according to claim 1, or the mammal or a progeny thereof, and evaluating the effectiveness of the test substance.

23. (Withdrawn) The method according to claim 22, wherein the immune-related pharmaceutical is a vaccine.

24. (Withdrawn) A method for producing immunocompetent cells, which is characterized in that it comprises recovering said immunocompetent cells from the mammal according to claim 1, or the mammal or a progeny thereof.

25. – 26. (Cancelled)

27. (Withdrawn) A method for producing immunocompetent cells, which is characterized in that it comprises recovering said immunocompetent cells from the mammal according to claim 20 or a progeny thereof.

28. – 33. (Cancelled)

34. (Previously Presented) The immunodeficient mammal according to claim 2, wherein the hematopoietic stem or precursor cells are derived from bone marrow, cord blood, or peripheral blood.

35. (Currently Amended) The immunodeficient mammal according to claim 2, wherein the immunocompetent cells ~~are at least one selected from the group consisting of B cells, T cells, dendritic cells, NK cells,~~ further comprise NK cells and NKT cells.

36. (Currently Amended) The immunodeficient mammal according to claim 2, wherein the physiologically active substance is a cytokine and/or an immunoglobulin, wherein the immunoglobulin comprises IgG, IgM, IgA and IgD.

37. (Currently Amended) The immunodeficient mammal according to claim 36, wherein the immunoglobulin ~~is any one selected from the group consisting of IgG, IgM, IgA, IgD,~~ and further comprises IgE.

38. (Currently Amended) The immunodeficient mammal according to ~~claim 2~~ any one of claims 2, 34, 35, 36 or 37, wherein the ~~NOD/SCID/IL2rg-null~~ SCID/IL2rg-null mammal is an NOD/SCID/IL2rg-null mouse.